about
Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human geneticsPrimary treatment of Crohn’s disease: combined antibiotics taking center stageInnate immunity in inflammatory bowel disease: a disease hypothesisSargramostim (GM-CSF) for induction of remission in Crohn's diseaseNew insights into the dichotomous role of innate cytokines in gut homeostasis and inflammationPivotal roles of GM-CSF in autoimmunity and inflammationMicrobiota biodiversity in inflammatory bowel diseaseGM-CSF: An immune modulatory cytokine that can suppress autoimmunityThe short-chain fatty acid receptor GPR43 is transcriptionally regulated by XBP1 in human monocytesApilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasisRole of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies?Medical management of Crohn's disease: current therapy and recent advances.The hematopoietic cytokine granulocyte-macrophage colony stimulating factor is important for cognitive functions.A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes.A cytokine-cytokine interaction in the assembly of higher-order structure and activation of the interleukine-3:receptor complex.Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing.Growth factors as treatment for inflammatory bowel disease: a concise review of the evidence toward their potential clinical utility.The role of the innate and adaptive immune system in pediatric inflammatory bowel disease.Recruitment of circulating breast cancer cells is stimulated by radiotherapy.Hematopoietic cell transplantation for Crohn's disease; is it time?Medical management of Crohn's disease.GM-CSF-facilitated dendritic cell recruitment and survival govern the intestinal mucosal response to a mouse enteric bacterial pathogen.Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.Heterozygous nucleotide-binding oligomerization domain-2 mutations affect monocyte maturation in Crohn's disease.Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor.Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactionsInfliximab and ulcerative colitis.Crohn's disease: innate immunodeficiency?Current and emerging drugs for the treatment of inflammatory bowel disease.Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis.Loss of GM-CSF signalling in non-haematopoietic cells increases NSAID ileal injuryEffect of live Salmonella Ty21a in dextran sulfate sodium-induced colitisSignal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitisCell Specific eQTL Analysis without Sorting Cells.Inflammatory bowel disease (IBD)-like disease in a case of a 33-year old man with glycogenosis 1b.Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD.Experimental colitis in mice is attenuated by topical administration of chlorogenic acid.The fundamental basis of inflammatory bowel disease.Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.Tumour necrosis factor alpha blockade induces an anti-inflammatory growth hormone signalling pathway in experimental colitis.
P2860
Q21131205-65C0F784-C0CD-43E3-A219-4B8222D91DF8Q22241483-E96E0C4E-74C5-4F00-A003-1762D057097DQ22252859-D922A0F5-FD6E-4F26-A336-FD0FA253161BQ24235068-3FBB2E8E-3C83-4283-82F7-E32DBA6C9699Q26823773-416747CB-74C6-4C4D-94A3-0F7EA565562FQ26830824-F4CA4608-DC69-464E-8C65-4C54E5DA22F7Q27027772-3C9341AE-68AC-4E3F-B928-8D1005E1FE1CQ28080640-CAFFA178-C8D5-442C-B426-55F5BE055378Q28256143-70CF6EB5-A030-454C-BB36-53EA554AD253Q28482161-5CB0732F-BCAD-4DFD-B6E7-D8D622C41E17Q30438775-6102E61B-4E65-4CB4-9CAF-63D6A8B41B11Q30450875-43ABC81E-D508-4D9C-A48C-CFE077CDA3EFQ30463376-AA31BF36-424B-45A3-9268-ECF6E3C7E806Q31171052-A380B34B-E2F7-41C9-A0E7-2998C007FBB4Q33427864-26460CDE-ED88-4C24-A127-E9F58C5D1FDDQ33694525-FFB43D07-F5A3-4698-BE80-D860F59C13E0Q33738131-2F441AD9-BB3E-45D3-B3D7-AFD0D4642831Q33830707-0A075230-46F7-467B-A87D-318B2BC31140Q33999214-8E71E22A-119F-4B41-AFED-F71B51F231F2Q34017756-961682AF-0E9E-41EE-ACDA-2CAC10D49508Q34046139-837045EF-F41F-48F6-9807-F2383F243A0DQ34058590-64956E76-E35D-4ACF-B498-4B4D8682C9D4Q34098754-E914D262-473A-406C-B8F7-1F07A32E3F94Q34225202-4187D4BF-2784-4D42-9C13-66702B419549Q34387000-98D22C47-120D-41B2-9C35-D47CA6DD1289Q34477550-559C127F-1454-4647-8E63-6FA6F9E888E2Q34503548-E1986D65-619B-4A81-A3B5-38C61CE2FDF8Q34581819-2CFA1A8B-D511-4D9B-8CA9-8748C53090F9Q34883210-F35B5DE6-8E62-49C0-A05C-85372EF357E0Q34918999-8EB58CD9-7644-4E19-9B53-E9C6230F2F25Q34976136-1BD67A81-F196-4A25-8905-EF252023131FQ35161765-494578F7-6E99-4C3F-90CB-3E387DAD1834Q35569874-9F858969-E062-4216-8FBA-BDDC174130E3Q35587187-6ACA1220-E109-4381-BC0C-A2E22F2580ABQ35604571-6FA02142-4D3C-4917-A3BF-4DBCC4E756A4Q35611467-C583ED9A-01EC-4FFB-BE2C-F716DD737F0EQ35626127-D6C0FA0B-C67F-42B9-9C4D-6602CE133065Q35649436-00434ED6-61B8-4488-B618-497DFEA06FF5Q35748693-DFC6DDF8-638F-467B-BBC2-01A4D5D6C1A4Q35761249-B4B2CD0B-44D9-4806-AB73-DB4CEE61DA79
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Sargramostim for active Crohn's disease
@ast
Sargramostim for active Crohn's disease
@en
Sargramostim for active Crohn's disease
@nl
type
label
Sargramostim for active Crohn's disease
@ast
Sargramostim for active Crohn's disease
@en
Sargramostim for active Crohn's disease
@nl
prefLabel
Sargramostim for active Crohn's disease
@ast
Sargramostim for active Crohn's disease
@en
Sargramostim for active Crohn's disease
@nl
P2093
P356
P1476
Sargramostim for active Crohn's disease
@en
P2093
Brian K Dieckgraefe
Diana F Hausman
John F Valentine
Joshua R Korzenik
Mark J Gilbert
P304
P356
10.1056/NEJMOA041109
P407
P577
2005-05-26T00:00:00Z